DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Trial Parameters
Brief Summary
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically confirmed relapsed or refractory ovarian cancer (including epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma). * Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non- nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. * Participants must have received at least one prior platinum-based chemotherapeutic regimen for primary management of disease. * Participants must have had six or fewer lines of prior systemic therapy. Maintenance treatments (e.g. PARP inhibitors, bevacizumab maintenance) and hormonal therapy (e.g. aromatase inhibitors) are not included as separate lines. For participants who received recent palliative radiotherapy, the radiation treatment must have been complet